Donafenib intolerance in hepatocellular carcinoma: severe hand–foot skin reaction and successful switch to lenvatinib – a case report and literature review
This case highlights the importance of early detection and accurate grading of HFSR, timely treatment interruption, and mechanism-informed switching to an alternative tyrosine kinase inhibitor such as lenvatinib. It also underscores key differences in toxicity profiles between donafenib-associated with VEGFR/RAF-related cutaneous injury-and lenvatinib, which is more commonly linked to hypertension, diarrhea, and appetite or weight changes.
Authors
- Ping Song (ORCID: https://orcid.org/0000-0003-1216-3184)
- Ying Chen (ORCID: https://orcid.org/0009-0008-4711-452X)
- Li‐Chen Fu (ORCID: https://orcid.org/0000-0002-6947-7646)
- Yuqi Jin
- Yinuo Tan
Institutions
- Wenzhou Medical University (CN)
- Zhejiang Cancer Hospital (CN)
- Second Affiliated Hospital of Zhejiang University (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-12-18
- DOI
- https://doi.org/10.3389/fonc.2025.1728098
- Citations
- 1
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Beijing Xisike Clinical Oncology Research Foundation
- National Natural Science Foundation of China